



PINNACLE — ANALYTICS —

Potency Results

Sample Name: SSC-23902B
Client: Indomira
Client Batch ID: C073GL-OOF

Pinnacle-Analytics.com
3549 Lear Way, Suite 101
Medford OR 97504
P:(541)300-8217

Sample ID: C-HS-367-D1810

Date Sampled: 11/1/2023

Matrix: Tincture

Date Reported: 11/8/2023

Prep Analyst: Jeff A.

Client License: AG-R1084850-IHH

Analysis Method: 0630322+1 H4 4-21-2022 #1.lcm

540 E Vilas Suite C

Sampling Method: Hemp Sampling SOP Rev 2

Central Point OR 97502

Reference Method: JCB 2009: HPLC/DAD


Analysis Batch: 11-3-2023 H4 205, 407, 128, 367 Solids

Total THC (THCA*0.877+d9-THC) **0.0918%**
Total CBD (CBDA*0.877+CBD) **3.64%**
Moisture Content N/A

| Cannabinoid | % Weight | mg/ml |
|---------------------------|--------------|-------------|
| CBDVA | <LOQ | <LOQ |
| CBDV | <LOQ | <LOQ |
| CBDA* | 0.107 | 1.03 |
| CBGA | <LOQ | <LOQ |
| CBG | <LOQ | <LOQ |
| CBD* | 3.55 | 34.1 |
| THCV | <LOQ | <LOQ |
| CBN | <LOQ | <LOQ |
| d9-THC* | 0.0918 | 0.881 |
| d8-THC* | <LOQ | <LOQ |
| CBC | 0.134 | 1.29 |
| THCA* | <LOQ | <LOQ |
| Total Cannabinoids | 3.883 | 37.3 |

*ORELAP Accredited Analyte

Limit Of Quantitation: 0.08%, analyte not measured



- CBDA*
- CBC
- CBD*
- d9-THC*



These test results may not be altered or reproduced except in full without the permission of Pinnacle Analytics. These results were generated following the Oregon Administrative Rules and in accordance with the NELAP Institute under ORELAP License #4152
Report generated by Routine_Potency_Rev13_8-1-2023

Kris Ford, PhD
Lab Director



PINNACLE — ANALYTICS —

Quality Control Results

Analyst: Jeff A.

Analysis Batch: 11-3-2023 H4 205, 407, 128, 367 Solids

Pinnacle-Analytics.com
3549 Lear Way, Suite 101
Medford OR 97504
P:(541)300-8217

| | Duplicate RPD | | LCS % Recovery | | Method Blank | |
|---------------|---------------|-------|----------------|---------|--------------|-------|
| | HS-0-D1772-b | Limit | C-SL-110323 | Limits | C-SB-110323 | Limit |
| CBDA | <LOQ% | 30% | 101.0% | 90-110% | <LOQ/2 | LOQ/2 |
| CBD | 1.73% | 10% | 105.0% | 90-110% | <LOQ/2 | LOQ/2 |
| d9-THC | 1.58% | 30% | 100.0% | 90-110% | <LOQ/2 | LOQ/2 |
| d8-THC | 4.19% | 30% | N/A% | 90-110% | <LOQ/2 | LOQ/2 |
| THCA | 1.65% | 10% | 92.5% | 90-110% | <LOQ/2 | LOQ/2 |

RPD: Relative Percent Difference between unknown sample and its duplicate

LCS: Laboratory Control Sample with known concentration

Case Comments: There were no divergences from ordinary Quality Control procedures or SOPs.



These test results may not be altered or reproduced except in full without the permission of Pinnacle Analytics. These results were generated following the Oregon Administrative Rules and in accordance with the NELAP Institute under ORELAP License #4152
Report generated by Routine_Potency_Rev13_8-1-2023

Kris Ford, PhD
Lab Director



Certificate of Analysis

Green Earth Medicinals
 2305 Ashland St, Suite C360
 Ashland, OR 97520
 Phone: 888-620-1110
 Fax:

Invoice Number: 23.1499
 PO Number: 110223
 Received Date: 11/06/2023
 Number of Samples: 01
 Project Name: Routine Testing

Microbiology Report:

| | | |
|---|------------------------|-------------------------|
| Lab #: 23-9369 | Sample Lot: SSC-23902B | Sample Date: |
| Sample Name: CBD Oral Sleep Spray Lemon -Lavender | Additional ID: | Plated Date: 11/06/2023 |
| Qualifying Material Number: No QM | | |

| Test Performed | Results | Units | Detection Limit | Method | Date Analyzed |
|---------------------------|---------|--------|-----------------|---------------------|---------------|
| Aerobic Plate Count | 10 | cfu/ml | 10 | USP 43-NF 38 <2021> | 11/09/2023 |
| Coliforms | <10 | cfu/ml | 10 | 02-228 | 11/08/2023 |
| <i>E. coli</i> | absent | P/A | 1 | USP 43-NF 38 <2022> | 11/09/2023 |
| <i>Staph aureus</i> | absent | P/A | 1 | USP 43-NF 38 <2022> | 11/09/2023 |
| Yeast | <10 | cfu/ml | 10 | USP 43-NF 38 <2021> | 11/11/2023 |
| Mold | <10 | cfu/ml | 10 | USP 43-NF 38 <2021> | 11/11/2023 |
| Salmonella | absent | P/A | 1 | USP 43-NF 38 <2022> | 11/10/2023 |
| <i>Pseudo. aeruginosa</i> | absent | P/A | 1 | USP 43-NF 38 <m62> | 11/09/2023 |

Approved By: QA Director SMV 11/13/2023

Confidential

Page 1 of 2

This Certificate/Report shall not be reproduced, except in full, without the prior written consent of KML Laboratories, Inc.

This report may include work not covered by KML's current ISO accreditation as indicated by ‡.

Note: On this date, this material met the specifications designated above, and is **not known if statistically representative of the lot evaluated on a routine basis**. This information is not intended to relieve the purchaser from its responsibility to determine the suitability of this material for purchaser's purposes, to comply with all laws and regulations regarding the safe use of this material. [nd = none detected above the listed detection limit](#)





Certificate of Analysis

Green Earth Medicinals
 2305 Ashland St, Suite C360
 Ashland, OR 97520
 Phone: 888-620-1110
 Fax:

Invoice Number: 23.1499
 PO Number: 110223
 Received Date: 11/06/2023
 Number of Samples: 01
 Project Name: Routine Testing

Microbiology Report:

| | | |
|---------------------------------------|--|-------------------------|
| Lab #: Control 11062023 | Additional ID: Negative Control Purposes | Plated Date: 11/06/2023 |
| Sample Name: Control 11062023 | | |
| Qualifying Material Number: QM-06-001 | | |

| Test Performed | Results | Units | Detection Limit | Method | Date Analyzed |
|---------------------------|---------|--------|-----------------|---------------------|---------------|
| Aerobic Plate Count | nd | cfu/ml | 10 | USP 43-NF 38 <2021> | 11/09/2023 |
| Coliforms | nd | cfu/ml | 10 | 02-228 | 11/08/2023 |
| <i>E. coli</i> | absent | P/A | 1 | USP 43-NF 38 <2022> | 11/09/2023 |
| <i>Staph aureus</i> | absent | P/A | 1 | USP 43-NF 38 <2022> | 11/09/2023 |
| Yeast | nd | cfu/ml | 10 | USP 43-NF 38 <2021> | 11/11/2023 |
| Mold | nd | cfu/ml | 10 | USP 43-NF 38 <2021> | 11/11/2023 |
| Salmonella | absent | P/A | 1 | USP 43-NF 38 <2022> | 11/10/2023 |
| <i>Pseudo. aeruginosa</i> | absent | P/A | 1 | USP 43-NF 38 <m62> | 11/09/2023 |

Approved By: QA Director SMV 11/13/2023

Confidential

Page 2 of 2

This Certificate/Report shall not be reproduced, except in full, without the prior written consent of KML Laboratories, Inc.

This report may include work not covered by KML's current ISO accreditation as indicated by ‡.

Note: On this date, this material met the specifications designated above, and is **not known if statistically representative of the lot evaluated on a routine basis**. This information is not intended to relieve the purchaser from its responsibility to determine the suitability of this material for purchaser's purposes, to comply with all laws and regulations regarding the safe use of this material. nd = none detected above the listed detection limit

